Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study)
Open accessThe DOI matches its Crossref record.
Abstract
Article Abstract Objective: Quetiapine, combined with lithium or divalproex, demonstrates efficacy in the maintenance treatment of bipolar I disorder. This study investigated the efficacy and safety of quetiapine monotherapy as maintenance treatment in bipolar I disorder compared with switching to placebo or lithium. Method: Patients aged ≥ 18 years with DSM-IV-diagnosed bipolar I disorder and a current or recent manic, depressive, or mixed episode received open-label quetiapine (300-800 mg/d) for 4-24 weeks. Patients achieving stabilization were randomized to continue quetiapine or to switch to placebo or lithium (0.6-1.2 mEq/L) for up to 104 weeks in a double-blind trial. Outcome measures included times to recurrence of any mood event (primary outcome measure), manic event, or depressive event. Safety assessments included adverse events and laboratory values. The study was terminated early after planned interim analysis provided positive results. The study was conducted between March 2005 and July 2007. Results: Of 2,438 patients starting open-label quetiapine, 1,226 (50.3%) were randomized to double-blind treatment, including 1,172 (95.6%) in the intent-to-treat population. Time to recurrence of any mood event was significantly longer for quetiapine versus placebo (hazard ratio = 0.29; 95% CI, 0.23-0.38; P < .0001) and for lithium versus placebo (HR = 0.46; 95% CI, 0.36-0.59; P < .0001). Quetiapine and lithium significantly increased time to recurrence of both manic events (quetiapine: HR = 0.29; 95% CI, 0.21-0.40; P < .0001; lithium: HR = 0.37; 95% CI, 0.27-0.53; P < .0001) and depressive events (quetiapine: HR = 0.30; 95% CI, 0.20-0.44; P < .0001; lithium: HR = 0.59; 95% CI, 0.42-0.84; P < .004) compared with placebo. Overall rates of adverse events were generally similar between treatment groups, and safety findings for quetiapine were consistent with its known profile. Conclusions: In patients stabilized during acute quetiapine treatment, continuation of quetiapine significantly increased time to recurrence of any mood, manic, or depressive event compared with switching to placebo. Switching to lithium was also more effective than placebo for the prevention of manic and depressive events. Trial Registration: clinicaltrials.gov Identifier: NCT00314184 J Clin Psychiatry © Copyright 2011 Physicians Postgraduate Press, Inc. Submitted: January 24, 2011; accepted July 28, 2011. Online ahead of print: October 18, 2011 (doi:10.4088/JCP.11m06878). Corresponding author: Richard H. Weisler, MD, Department of Psychiatry and Behavioral Science, Duke University Medical Center, Department of Psychiatry, University of North Carolina at Chapel Hill, 700 Spring Forest, Ste 125, Raleigh, NC 27609 (RWeisler@aol.com).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lithium (level 1),368, 369 quetiapine (level 1),369, 370 divalproex (level 1) 369, 371, 372 (Figure 4) and lamotrigine (level 1)369, 373 monotherapies have the best combination of clinical trials, administrative data, and clinical experience to support their use as first‐line therapies for maintenance treatment of BD.”
In the citing paper
“Further, there is evidence that oral quetiapine and long‐acting injectable risperidone monotherapy and adjunctive therapy and oral ziprasidone adjunctive therapy are effective in preventing mood episodes in adults with BD.369, 370, 383, 384, 387”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationGeddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Won, E., & Kim, Y.-K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122679 · Cited by 223
Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis
Severus, E., Taylor, M. J., Sauer, C., Pfennig, A., Ritter, P., Bauer, M., & Geddes, J. R. (2014) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0015-8 · Cited by 216
The suicide prevention effect of lithium: more than 20 years of evidence—a narrative review
Lewitzka, U., Severus, E., Bauer, R., Ritter, P., Müller-Oerlinghausen, B., & Bauer, M. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-015-0032-2 · Cited by 196
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Patients with a mixed index episode had a significantly lower risk of a relapse into a new manic episode (HR (95% CI) 0.34 (0.12–0.95)) and episode of any type compared to placebo (HR (95% CI) 0.48 (0.27–0.86))(Weisler et al. 2011; Nolen and Weisler 2013).”
BackgroundInfluentialWeight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 187
Diagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 206
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169
Nolen, W. A., Licht, R. W., Young, A. H., Malhi, G. S., Tohen, M., Vieta, E., Kupka, R. W., Zarate, C., Nielsen, R. E., Baldessarini, R. J., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12805 · Cited by 164
Self-citationAltamura, A. C., Buoli, M., Caldiroli, A., Caron, L., Cumerlato Melter, C., Dobrea, C., Cigliobianco, M., & Zanelli Quarantini, F. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.024 · Cited by 162
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Kessing, L. V., Bauer, M., Nolen, W. A., Severus, E., Goodwin, G. M., & Geddes, J. R. (2018) · Bipolar Disorders · doi:10.1111/bdi.12623 · Cited by 143
Self-citationEfficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Lindström, L., Lindström, E., Nilsson, M., & Höistad, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.012 · Cited by 122
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Yatham, L. N., Chakrabarty, T., Bond, D. J., Schaffer, A., Beaulieu, S., Parikh, S. V., McIntyre, R. S., Milev, R. V., Alda, M., Vázquez, G. H., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13135 · Cited by 136
Vázquez, G. H., Holtzman, J. N., Lolich, M., Ketter, T. A., & Baldessarini, R. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.013 · Cited by 102
“…1981; Prien et al., 1984; Greil et al., 1997; Bowden et al., 2003; Calabrese et al., 2003; Hartong et al., 2003; Tohen et al., 2004; Findling et al.; 2005; Keck et al., 2007; Vieta et al., 2008; Suppes et al., 2009; Geddes et al. 2010; Quiroz et al., 2010; Weisler et al., 2011; Vieta et al., 2012).”
InfluentialBerk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-91 · Cited by 96
Nestsiarovich, A., Gaudiot, C., Baldessarini, R. J., Vieta, E., Zhu, Y., & Tohen, M. F. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.08.264 · Cited by 107
Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management
Fang, F., Sun, H., Wang, Z., Ren, M., Calabrese, J. R., & Gao, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0352-5 · Cited by 104
Quetiapine: A Review of its Use in the Management of Bipolar Depression
Sanford, M., & Keating, G. M. (2012) · CNS Drugs · doi:10.2165/11203840-000000000-00000 · Cited by 88
Berk, M., Daglas, R., Dandash, O., Yücel, M., Henry, L., Hallam, K., Macneil, C., Hasty, M., Pantelis, C., Murphy, B. P., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.186833 · Cited by 69
Carlborg, A., Ferntoft, L., Thuresson, M., & Bodegard, J. (2015) · Bipolar Disorders · doi:10.1111/bdi.12234 · Cited by 72
Nolen, W. A., & Weisler, R. H. (2013) · Bipolar Disorders · doi:10.1111/bdi.12027 · Cited by 73
Self-citationNabi, Z., Stansfeld, J. L., Plöderl, M., Wood, L., & Moncrieff, J. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602200049x · Cited by 79
Maintenance therapies in bipolar disorders
Gitlin, M., & Frye, M. A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00992.x · Cited by 70
Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review
Carvalho, A. F., Quevedo, J., McIntyre, R. S., Soeiro-de-Souza, M. G., Fountoulakis, K. N., Berk, M., Hyphantis, T. N., & Vieta, E. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu079 · Cited by 66
Verdolini, N., Hidalgo‐Mazzei, D., Murru, A., Pacchiarotti, I., Samalin, L., Young, A. H., Vieta, E., & Carvalho, A. F. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12896 · Cited by 67
The case for improved care and provision of treatment for people with first-episode mania
Jauhar, S., Ratheesh, A., Davey, C. G., Yatham, L. N., McGorry, P. D., McGuire, P. K., Berk, M., & Young, A. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30082-3 · Cited by 72
Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012
Kanba, S., Kato, T., Terao, T., Yamada, K., & Committee for Treatment Guidelines of Mood Disorders, J. S. O. M. D. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12060 · Cited by 68
Lithium for bipolar disorder: a review of the recent literature
Curran, G., & Ravindran, A. V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.947965 · Cited by 68
Bipolar and psychotic disorders in elite athletes: a narrative review
Currie, A., Gorczynski, P. F., Rice, S., Purcell, R., McAllister-Williams, H., Hitchcock, M., Hainline, B. W., & Reardon, C. L. (2019) · British Journal of Sports Medicine · doi:10.1136/bjsports-2019-100685 · Cited by 66
Buoli, M., Serati, M., & Altamura, A. C. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.08.024 · Cited by 61
Calabrese, J. R., Pikalov, A., Streicher, C., Cucchiaro, J., Mao, Y., & Loebel, A. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.013 · Cited by 55
Kessing, L. V. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-023-00322-7 · Cited by 63
Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium
Ketter, T. A., Miller, S., Dell’Osso, B. M., & Wang, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.002 · Cited by 62
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Girardi, P., Brugnoli, R., Manfredi, G., & Sani, G. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0139-7 · Cited by 61
Brunner, E., Tohen, M., Osuntokun, O., Landry, J., & Thase, M. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.101 · Cited by 49
Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update
Muneer, A. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.25 · Cited by 54
Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Psychological Medicine · doi:10.1017/s0033291720003505 · Cited by 48
Young, A. H., McElroy, S. L., Olausson, B., Paulsson, B., (D1447C00001), O. B. O. T. E. I., & Embolden II (D1447C00134) Investigators (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665177 · Cited by 46
Self-citationReversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression
Yatham, L. N., Arumugham, S. S., Kesavan, M., Ramachandran, K., Murthy, N. S., Saraf, G., Ouyang, Y., Bond, D. J., Schaffer, A., Ravindran, A. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300184 · Cited by 45
Severus, E., Bauer, M., & Geddes, J. R. (2018) · Pharmacopsychiatry · doi:10.1055/a-0627-7489 · Cited by 46
Rating Scales in Bipolar Disorder
Sajatovic, M., Chen, P., & Young, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00009-9 · Cited by 57
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000–2011
Hooshmand, F., Miller, S., Dore, J., Wang, P. W., Hill, S. J., Portillo, N., & Ketter, T. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.054 · Cited by 43
Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-10 · Cited by 35
“The adverse event profile in this patient population was qualitatively similar to findings in acute and maintenance studies of quetiapine monotherapy in patients with bipolar I or II disorder (Bowden et al. 2005; McIntyre et al. 2005; Weisler et al. 2011).”
ResultNolen, W. A. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0017-6 · Cited by 43
Self-citationHsu, C., Tsai, S., Tseng, P., Liang, C., Vieta, E., Carvalho, A. F., Stubbs, B., Kao, H.-Y., Tu, Y., & Lin, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.112 · Cited by 35
Lithium, but not Valproate, Reduces Impulsive Choice in the Delay-Discounting Task in Mice
Halcomb, M., Gould, T. D., & Grahame, N. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.89 · Cited by 34
Effects of quetiapine on DNA methylation in neuroblastoma cells
Sugawara, H., Bundo, M., Asai, T., Sunaga, F., Ueda, J., Ishigooka, J., Kasai, K., Kato, T., & Iwamoto, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.010 · Cited by 32
Carli, M., Weiss, F., Grenno, G., Ponzini, S., Kolachalam, S., Vaglini, F., Viaggi, C., Pardini, C., Tidona, S., Longoni, B., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230224102318 · Cited by 43
Antipsychotic switching in bipolar disorders: a systematic review
Grande, I., Bernardo, M., Bobes, J., Saiz-Ruiz, J., Álamo, C., & Vieta, E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001168 · Cited by 30
Lithium as the drug of choice for maintenance treatment in bipolar disorder
Kessing, L. V. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13070 · Cited by 30
Shuy, Y. K., Santharan, S., Chew, Q. H., & Sim, K. (2024) · Brain Sciences · doi:10.3390/brainsci14010102 · Cited by 28
Findling, R. L., Pathak, S., Earley, W. R., Liu, S., & DelBello, M. P. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0092 · Cited by 29
Mohammad, O., & Osser, D. N. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000018 · Cited by 27
Wingård, L., Brandt, L., Bodén, R., Kieler, H., Andersen, M. T., & Reutfors, J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.04.003 · Cited by 27
Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy
Malhi, G. S., McAulay, C., Das, P., & Fritz, K. (2014) · Evidence-Based Mental Health · doi:10.1136/eb-2014-101948 · Cited by 27
Treating mixed mania/hypomania: a review and synthesis of the evidence
Takeshima, M. (2016) · CNS Spectrums · doi:10.1017/s1092852916000845 · Cited by 26
Antipsychotics in the Treatment of Bipolar Disorder
Singh, J. B., Chen, G., & Canuso, C. M. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_8 · Cited by 31
Thronson, L. R., & Pagalilauan, G. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.001 · Cited by 27
Geddes, J. R., & Miklowitz, D. J. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.205 · Cited by 22
Cheng, C., Chang, W. H., Lin, Y., Chen, P. S., Yang, Y. K., & Bai, Y. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103480 · Cited by 24
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Wang, J. X., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Rhee, T. G., Ho, R., Lo, H. K. Y., Goldberg, J. F., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119487 · Cited by 25
Cipriani, A., Barbui, C., Rendell, J., & Geddes, J. R. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12223 · Cited by 20
Antipsychotic switching in schizoaffective disorder: A systematic review
Murru, A., Hidalgo, D., Bernardo, M., Bobes, J., Sáiz-Ruiz, J., Álamo, C., & Vieta, E. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1012225 · Cited by 19
Bai, Y., Yang, H., Chen, G., & Gao, K. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001169 · Cited by 21
Lithium as a disease-modifying drug for bipolar disorder
Post, R. M., Li, V. W., Berk, M., & Yatham, L. N. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00097-5 · Cited by 24
Antipsychotic Drugs and Dysregulated Glucose Homeostasis: A Systematic Review and Meta-Analysis
Smith, E. C. C., Agarwal, S. M., Panganiban, K. J., Maksyutynska, K., Monteiro, J., Lee, J., Prasad, F., Ji, A., Shah, D., Cavalier, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2240 · Cited by 23
Mishu, M. P., Uphoff, E., Aslam, F., Philip, S., Wright, J. M., Tirbhowan, N., Ajjan, R., Azdi, Z. A., Stubbs, B., Churchill, R. C., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013281.pub2 · Cited by 23
Bschor, T., & Bauer, M. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3766-z · Cited by 22
Management of inter-episodic periods in patients with bipolar disorder
Samalin, L., Murru, A., & Vieta, E. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1176530 · Cited by 19
Gao, K., Goto, T., Yuan, C., Brownrigg, B., Conroy, C. M., Chan, P. K., Serrano, M. B., Ganocy, S. J., Fang, F., & Calabrese, J. R. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000927 · Cited by 18
Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy
Janicak, P. G., & Rado, J. T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.681377 · Cited by 15
Porter, R., Inder, M., Douglas, K. M., Moor, S., Carter, J. D., Frampton, C. M., & Crowe, M. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419887794 · Cited by 16
Escudero, M. A. G., Gutiérrez-Rojas, L., & Lahera, G. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09753-2 · Cited by 19
Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung
Bschor, T., Müller-Oerlinghausen, B., Stoppe, G., & Hiemke, C. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4083-x · Cited by 16
Pharmacological treatment of mixed states
Cuomo, A., Nikolova, V. L., Yalin, N., Arnone, D., Fagiolini, A., & Young, A. H. (2017) · CNS Spectrums · doi:10.1017/s1092852917000013 · Cited by 14
Quetiapine: A Pharmacoeconomic Review of its Use in Bipolar Disorder
Plosker, G. L. (2012) · PharmacoEconomics · doi:10.2165/11208500-000000000-00000 · Cited by 18
Effect of lithium on suicide and mortality in mood disorders: A systematic review
Börjesson, J., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-190058 · Cited by 16
History of Suicide Prevention with Lithium Treatment
Tondo, L., & Baldessarini, R. J. (2025) · Pharmaceuticals · doi:10.3390/ph18020258 · Cited by 14
Clinical decision making in the treatment of mixed states
Grunze, H., & Azorin, J. M. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.908238 · Cited by 12
Systematic Review of Recent Guidelines for Pharmacological Treatments of Bipolar Disorders in Adults
Hammett, S., & Youssef, N. A. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900409 · Cited by 14
The Contributions of Lithium and Clozapine for the Prophylaxis and Treatment of Suicidal Behavior
Müller-Oerlinghausen, B., & Lewitzka, U. (2015) · Advances in biological psychiatry · doi:10.1159/000434747 · Cited by 13
Long-Term Treatment of Mood Disorders
Nolen, W. A., & Grunze, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00004-x · Cited by 12
Self-citationWang, Z., Zhang, D., Du, Y., Wang, Y., Huang, T., Ng, C. H., Huang, H., Pan, Y., Lai, J., & Hu, S. (2023) · Pharmaceuticals · doi:10.3390/ph16020287 · Cited by 11
Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-145 · Cited by 9
“Nevertheless, among atypical antipsychotics, only quetiapine has been reported to show relatively equivalent efficacy in preventing both manic and depressive episodes [21,22].”
BackgroundMcIntyre, R. S., Davis, B., Rodgers, J., Rekeda, L., Adams, J., & Yatham, L. N. (2024) · Bipolar Disorders · doi:10.1111/bdi.13421 · Cited by 9
Weisler, R. H., & McIntyre, R. S. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846520 · Cited by 9
Self-citationBerger, M., Riedel, M. J., Tomova, N., Obermeier, M., Seemüller, F., Dittmann, S., Mœller, H., & Severus, E. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-7 · Cited by 8
Pharmacologic Treatment of Mixed States
Pompili, M., Vázquez, G. H., Forte, A. M., Morrissette, D. A., & Stahl, S. M. (2019) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2019.10.015 · Cited by 10
Locklear, J. C., Alemayehu, B., Brody, R. S., Chavoshi, S., Tunceli, O., Kern, D. M., & Earley, W. R. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.005 · Cited by 7
Timing of onset of lithium relapse prevention in bipolar disorder: evidence from randomised trials
Taylor, M. J. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.177 · Cited by 7
Can we check serum lithium levels less often without compromising patient safety?
Heald, A. H., Holland, D., Stedman, M., Davies, M., Duff, C. J., Parfitt, C., Green, L., Scargill, J., Taylor, D. M., & Fryer, A. A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1027 · Cited by 8
Metadata
- Authors
- Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Weisler, Richard H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-11-15
- Volume
- 72
- Issue
- 11
- Pages
- 1452-1464
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034480582
- Cited by
- 169
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 12 · 2015: 15 · 2014: 23 · 2013: 23 · 2012: 15
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Universidad Peruana Cayetano Heredia Institutional Repository (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- quetiapine, bipolar I disorder, maintenance therapy, lithium, mood stabilizers, relapse prevention, manic episodes, depressive episodes, drug switching, adverse events, atypical antipsychotics, lithium toxicity, divalproex, open-label extension, early trial termination
- MeSH terms
- Quetiapine Fumarate, Adult, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lithium, Male, Middle Aged, Placebos, Antipsychotic Agents, Proportional Hazards Models, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.